HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Triple inhaled drug protocol for the treatment of acute severe asthma.

AbstractSTUDY OBJECTIVE:
This study tests the hypothesis that the administration of multiple doses of inhaled albuterol (A), ipratropium bromide (IB), and flunisolide (F) provides an additional benefit to adults with acute severe asthma compared with the administration of A plus IB (A/IB) or A plus F (A/F).
DESIGN:
Randomized, double-blind, prospective trial.
PATIENTS AND INTERVENTIONS:
One hundred seventy-two patients who presented to an emergency department were assigned to receive A, IB, and F (ie, triple drug treatment [TDG]; 56 patients), A/IB (60 patients), or A/F (56 patients). All drugs were administered through a metered-dose inhaler and spacer at 10-min intervals for 3 h.
RESULTS:
Patients who received TDG had an overall 64% greater improvement (95% confidence interval [CI], 24 to 103%; p = 0.002) in FEV(1) (mean [+/- SD], 2.1 +/- 0.6 L) than those who received A/F (mean, 1.7 +/- 0.6 L), and a 41% greater improvement (95% CI, 1 to 80%; p = 0.04) than those who received A/IB (mean, 1.8 +/- 0.6 L). Differences between groups increased with time (p = 0.001). At 3 h, there was a trend toward a reduction in hospital admission rates (A/IB group, 25%; A/F group, 20%; and TDG group, 11%). The patients who were the most likely to benefit (ie, those with a greater improvement in pulmonary function and a significant reduction in the hospitalization rate) from TDG were those with more severe obstruction (ie, FEV(1), < 30% of predicted). The benefit of TDG was equally evident independent of the patient's previous use of corticosteroids.
CONCLUSIONS:
The data suggest that there was a therapeutic benefit from the addition of IB and F to A administered in high doses, particularly in those patients in whom the FEV(1) was < 30% of the predicted value.
AuthorsGustavo J Rodrigo, Carlos Rodrigo
JournalChest (Chest) Vol. 123 Issue 6 Pg. 1908-15 (Jun 2003) ISSN: 0012-3692 [Print] United States
PMID12796167 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Adrenergic beta-Agonists
  • Bronchodilator Agents
  • Steroids, Fluorinated
  • Fluocinolone Acetonide
  • flunisolide
  • Ipratropium
  • Albuterol
Topics
  • Acute Disease
  • Administration, Inhalation
  • Adrenergic beta-Agonists (administration & dosage)
  • Adult
  • Albuterol (administration & dosage)
  • Asthma (drug therapy)
  • Bronchodilator Agents (administration & dosage)
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Fluocinolone Acetonide (administration & dosage, analogs & derivatives)
  • Forced Expiratory Volume
  • Humans
  • Ipratropium (administration & dosage)
  • Male
  • Prospective Studies
  • Steroids, Fluorinated (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: